Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i EVENTS
26 august 2017, Barcelona, Spain
ESC 2017: New approaches to targeting residual cardiovascular risk
Read full report..
R3i editorial
13 February 2018

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Optimizing treatment benefit: the tenet of personalized medicineRead more...

Cardiovascular disease (CVD) poses an increasing global burden. While novel therapeutic approaches have undoubtedly reduced morbidity and mortality in the acute coronary setting, the corresponding increase in life expectancy in chronic ischaemic heart disease and heart failure has had a substantial impact on healthcare systems and society as a whole. In the European Union, the annual cost of CVD to the economy is €210 billion, about half of which is due to healthcare costs, 26% to productivity losses and 21% to the informal care of people with CVD. CVD is responsible for the loss of more than 26 million disability-adjusted life years (DALYs), representing about one-fifth of all DALYs lost. In cost-conscious healthcare systems, ageing populations, together with an increasing prevalence of cardiometabolic disease, mandates the need for new approaches to CVD management...
landmark study
13 February 2018

More from CANTOS: Predicting patients likely to benefit most Read more...

The CANTOS study can be regarded as a landmark proof–of-concept study, which showed that targeting inflammation with canakinumab, a human monoclonal antibody to interleukin-1β, significantly reduced major adverse cardiovascular event rates in the absence of effects on LDL-C.
focus on...
13 February 2018

Remnant cholesterol: a novel target for reducing lipid-related residual cardiovascular risk Read more...

The gene APOC3 encodes apolipoprotein CIII (apoCIII), which is a key inhibitor of triglyceride lipolysis and clearance of remnant triglyceride-rich lipoproteins. Previous studies have indicated a causal link between carriage of APOC3 LOF mutations, characterized by low plasma triglycerides and low levels of apoCIII, and...
SCIENTIFIC SESSIONS
Looking to the American College of Cardiology Scientific Sessions 2018
67th Annual Scientific Sessions of the American College of Cardiology, 10-12 March, Orlando, USA.
Read more..
This year’s Scientific Sessions offers new insights from CANTOS and COMPASS, as well as novel approaches targeting elevated triglycerides and lipoprotein(a). Added to this, the second of the cardiovascular outcomes studies with PCSK9 monoclonal antibody therapy, ODYSSEY Outcomes with alirocumab in patients with a recent acute coronary syndrome, is keenly anticipated.
recent publication

Adverse effects of high HDL-C?Read more...

Findings from this large general population study indicate a U-shaped relationship between plasma high-density lipoprotein cholesterol (HDL-C) concentration and mortality....
recent publication

Metabolic syndrome severity predicts future coronary events in type 2 diabetesRead more...

Results from this analysis of the Atherosclerosis Risk in Communities study indicate that the severity of metabolic syndrome, estimated by...
recent publication

Atherogenic dyslipidaemia common in Chinese patients at LDL-C goalRead more...

Data from the Dyslipidemia International Survey-China study highlight a high prevalence of atherogenic dyslipidaemia among individuals attaining low-density lipoprotein cholesterol...
recent publication

Cost of diabetic complications in GermanyRead more...

This new study underlines the economic impact of complications of type 2 diabetes in Germany, based on nationwide data from316,220...
recent publication

Serum C-peptide: a contributor to lipid-related residual risk in the elderly?Read more...

Serum levels of C-peptide, an important risk factor for cardiovascular disease, are known to increase with age. This population-based cross-sectional...
recent publication

Well-being linked with lower triglycerides and high HDL-CRead more...

Finally, there is a report from the Midlife in the U.S. study that persistently high levels of psychological well-being measures...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARαMs in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.